Table 1. Patient demographics and baseline disease characteristics.
Characteristics | N=53 (%) |
---|---|
Age, years | |
Mean±SD | 55±12 |
Range | 24-83 |
Male gender, n (%) | 31 (59) |
WHO performance status, n (%) | |
Grade 0 | 29 (55) |
Grade 1 | 23 (43) |
Grade 2 | 1 (2) |
Primary site of cancer, n (%) | |
Small intestine | 21 (40) |
Stomach | 12 (23) |
Colon | 3 (6) |
Other* | 17 (32) |
Time on imatinib, n (%) | |
<6 months | 2 (4) |
≥6-<12 months | 3 (6) |
≥12-<24 months | 6 (11) |
≥24 months | 42 (79) |
Other prior tyrosine kinase inhibitor treatment, n (%) | |
Sunitinib | 33 (62) |
AMG706, RAD001, dasatinib, or VEG10003 | 12 (23) |
Includes colon, peritoneum, rectum and other abdominal sites
SD=Standard deviation; WHO=World Health Organization